Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,347 result(s) found. Displaying page 798 of 2,218.
    «« First « Previous 794  795  796  797  798  799  800  801  802  Next» Last»»
    EudraCT Number: 2012-005183-94 Sponsor Protocol Number: CLAF237AFR07 Start Date*: 2013-03-25
    Sponsor Name:Novartis Pharma S.A.S.
    Full Title: Etude multicentrique, randomisée, contrôlée, en ouvert d'une durée de 24 semaines, comparant la stratégie metformine/vildagliptine + insuline basale versus metformine/sulfamide + insuline basale ch...
    Medical condition: Diabète de type II
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003041-10 Sponsor Protocol Number: CRFB002H2301 Start Date*: 2015-04-14
    Sponsor Name:NOVARTIS FARMA S.p.A.
    Full Title: RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of prematu...
    Medical condition: Retinopathy of prematurity (ROP)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) EE (Completed) LT (Completed) HU (Completed) BE (Completed) AT (Completed) DE (Completed) GB (Completed) HR (Completed) FR (Completed) SK (Completed) CZ (Completed) GR (Completed) DK (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-006066-34 Sponsor Protocol Number: 105987,105988 Start Date*: 2015-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, single-blind, randomized, controlled, multinational study for the evaluation of safety of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-t...
    Medical condition: Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028911 Neisseria meningitidis infection NOS LLT
    18.0 100000004862 10018953 Haemophilus influenzae meningitis LLT
    18.0 100000004862 10018952 Haemophilus influenzae infection LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000276-10 Sponsor Protocol Number: FAST2015 Start Date*: 2015-07-02
    Sponsor Name:FAST Consortium under EU 7. FWP
    Full Title: FAST – Food Allergy Specific ImmunoTherapy A multinational phase IIb study to investigate the efficacy and safety of subcutaneous immunotherapy with a modified fish- parvalbumin given in single ri...
    Medical condition: Food allergy to fish
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed) DK (Completed) GR (Ongoing) NL (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002758-11 Sponsor Protocol Number: D4420C00005 Start Date*: 2015-10-21
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
    Medical condition: Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001356-31 Sponsor Protocol Number: PEN-PV Start Date*: 2015-05-20
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) AT (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005545-12 Sponsor Protocol Number: Start Date*: 2012-03-02
    Sponsor Name:University of Leicester
    Full Title: Enhanced Control of Hypertension and Thrombolysis Stroke Trial
    Medical condition: Acute Ischaemic Stroke
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002718-38 Sponsor Protocol Number: 111670 Start Date*: 2015-06-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, controlled, multi-center study to evaluate the long-term antibody persistence at 1 year, 3 years and 5 years after the administration of one dose of GlaxoSmithKline (GSK) Biologic...
    Medical condition: Invasive disease caused by Neisseria meningitidis serogroups A, C W-135 and Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028910 Neisseria meningitides meningitis LLT
    18.0 100000004862 10051931 Neisseria infection NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001554-15 Sponsor Protocol Number: 2014_01 Start Date*: 2015-08-13
    Sponsor Name:CHRU de Lille
    Full Title: Study controls feasibility of an intrapleural photodynamic therapy integrated into a multimode treatment associating a pleurectomy/extended hulling, a radiotherapy and an auxiliary chemotherapy amo...
    Medical condition: Malignant pleural mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003048-37 Sponsor Protocol Number: HSJC-CAR-01-2015 Start Date*: 2015-11-13
    Sponsor Name:Juan Luis Bonilla Palomas
    Full Title: Effect of ?-3 polyunsaturated fatty acids on serum albumin concentration in patients with acute heart failure, hypoalbuminemia, and high inflammatory activity
    Medical condition: Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003492-36 Sponsor Protocol Number: PS0003 Start Date*: 2015-03-12
    Sponsor Name:UCB Biopharma, SPRL
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- And Active-Controlled Study Followed By A Placebo-Controlled Maintenance Period And Open-Label Follow-Up To Evaluate The E...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018190 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) CZ (Completed) NL (Completed) PL (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005718-20 Sponsor Protocol Number: 111315 Start Date*: 2015-04-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase 2, open, randomized, controlled, multi-center study to evaluate the safety and immunogenicity of 7 infant immunization schedules of the RTS,S/AS01E candidate vaccine against P. falciparum.
    Medical condition: Healthy volunteers (Primary immunization against Plasmodium falciparum malaria)
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000933-21 Sponsor Protocol Number: B1971017 Start Date*: 2015-07-06
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2, RANDOMIZED, CONTROLLED, OBSERVER-BLINDED STUDY TO DESCRIBE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF NEISSERIA MENINGITIDIS SEROGROUP B BIVALENT RECOMBINANT LIPOPROTEIN 2086 VACCIN...
    Medical condition: Invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-002523-42 Sponsor Protocol Number: D3250C00020 Start Date*: 2014-06-24
    Sponsor Name:AstraZeneca AB
    Full Title: A multicenter, randomized, double-blind, parallel group, placebo-controlled, Phase 3 efficacy and safety study of benralizumab (MEDI-563) to reduce oral corticosteroid use in patients with uncontro...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-004281-25 Sponsor Protocol Number: MLN1117-1501 Start Date*: 2015-08-25
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Medical condition: non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Ongoing) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000582-31 Sponsor Protocol Number: AGLU3306 Start Date*: 2015-04-15
    Sponsor Name:Genzyme Corporation Inc
    Full Title: An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Myozyme® (alglucosidase alfa) Treatment in Patients with Pompe Disease Who Do Not Have an Optimal R...
    Medical condition: Pompe disease (acid alpha-glucosidase deficiency)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10036143 Pompe's disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002780-42 Sponsor Protocol Number: TR701-111 Start Date*: 2015-06-29
    Sponsor Name:Trius Therapeutics [...]
    1. Trius Therapeutics
    2. Cubist Pharmaceuticals, Inc
    Full Title: A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Ad...
    Medical condition: Acute bacterial skin and skin structure infections
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10040879 Skin investigations HLGT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005272-34 Sponsor Protocol Number: 42703 Start Date*: 2013-01-28
    Sponsor Name:Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose NVALT
    Full Title: Iressa RE-challenge in advanced NSCLC EGFR mutated patients who responded to an EGFR-TKI used as first-line or previous treatment.
    Medical condition: Non small cell lung cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012897-12 Sponsor Protocol Number: BIA-91067-202 Start Date*: 2009-12-08
    Sponsor Name:BIAL-Portela & Ca, SA
    Full Title: A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyl...
    Medical condition: Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-000370-19 Sponsor Protocol Number: CO-1686-022 Start Date*: 2015-01-14
    Sponsor Name:Clovis Oncology, Inc.
    Full Title: TIGER-1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 794  795  796  797  798  799  800  801  802  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 07:27:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA